Abstract: Na/K-ATPase ligands are provided that comprise a compound of formula (I) and are capable of binding to the ?1 Na/K-ATPase and decreasing the endocytosis of ?1 Na/K-ATPase, such that expression of the ?1 Na/K-ATPase is restored in the plasma membrane of cells and tumor growth and invasion is reduced. Pharmaceutical compositions are further provided that include a compound of formula (I) and a pharmaceutically-acceptable vehicle, carrier, or excipient. Methods of treating a cancer are further included and comprise administering to a subject an effective amount of a Na/K-ATPase ligand.